Omnicell Inc (OMCL)

Currency in USD
50.38
+0.08(+0.16%)
Real-time Data·
Earnings results expected in 10 days
OMCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
50.0751.00
52 wk Range
22.6655.00
Key Statistics
Prev. Close
50.3
Open
50.3
Day's Range
50.07-51
52 wk Range
22.66-55
Volume
44.12K
Average Vol. (3m)
517.87K
1-Year Change
15.4939%
Book Value / Share
26.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OMCL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
55.00
Upside
+9.17%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

Omnicell Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Omnicell Inc Company Profile

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Omnicell Inc SWOT Analysis


Innovation Pipeline
Delve into Omnisphere's potential as a key growth catalyst, leveraging AI and cloud technology to revolutionize pharmacy automation and efficiency
Financial Outlook
Analysts project modest 3% revenue growth for FY25, with a $40 price target from Wells Fargo Securities, reflecting cautious optimism amid transition
Market Dynamics
Explore how Omnicell navigates regulatory uncertainties and hospital spending trends while maintaining a strong foothold in medication management solutions
SaaS Transformation
Omnicell's strategic shift to SaaS and automation in pharmacy operations promises consistent revenue streams and enhanced market positioning
Read full SWOT analysis

Omnicell Inc Earnings Call Summary for Q3/2025

  • Omnicell's Q3 2025 EPS of $0.51 beat forecasts by 41.67%, with revenue of $310.63M exceeding expectations by 5.08%, driving stock up 14.81% in pre-market trading
  • Revenue increased 10% year-over-year to $311M, though non-GAAP EPS declined slightly from Q3 2024; the company completed a $75M stock repurchase program reducing shares by 5%
  • CEO Randall Lipps highlighted the company's transformation into an intelligence medication management technology leader, emphasizing the Omnisphere cloud platform
  • Q4 2025 revenue guidance set at $306-316M with full-year guidance of $1.177-1.187B; Annual Recurring Revenue expected to reach $610-630M by year-end
  • Despite strong performance, the company faces challenges from potential tariff impacts, though it expects to reduce these effects in 2026
Last Updated: 10/30/2025, 09:42 AM
Read Full Transcript
Omnicell investor slides for Q3/2025
Omnicell Q3 2025 slides
Last Update: Oct 30, 2025
See full investor slides

Compare OMCL to Peers and Sector

Metrics to compare
OMCL
Peers
Sector
Relationship
P/E Ratio
114.4x31.3x−0.6x
PEG Ratio
0.540.250.00
Price / Book
1.9x4.7x2.6x
Price / LTM Sales
1.9x4.6x3.4x
Upside (Analyst Target)
5.4%6.2%41.8%
Fair Value Upside
Unlock−0.1%4.8%Unlock

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 55.00
(+9.17% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BofA Securities
Hold53.00+5.18%46.00MaintainJan 16, 2026
KeyBanc
Buy60.00+19.07%-UpgradeJan 08, 2026
Wells Fargo
Sell52.00+3.20%43.00MaintainJan 05, 2026
BofA Securities
Hold46.00-8.71%36.00MaintainDec 09, 2025
Benchmark
Buy50.00-0.77%45.00MaintainDec 09, 2025

Earnings

Latest Release
Oct 30, 2025
EPS / Forecast
0.51 / 0.36
Revenue / Forecast
310.63M / 295.60M
EPS Revisions
Last 90 days

OMCL Income Statement

People Also Watch

233.63
CIEN
+1.96%
11.345
ONDS
-6.78%
131.29
CRDO
-1.40%
29.72
TDC
+1.23%
478.50
SNDK
+0.99%

FAQ

What Is the Omnicell (OMCL) Stock Price Today?

The Omnicell stock price today is 50.38

What Stock Exchange Does Omnicell Trade On?

Omnicell is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Omnicell?

The stock symbol for Omnicell is "OMCL."

What Is the Omnicell Market Cap?

As of today, Omnicell market cap is 2.26B.

What Is Omnicell's Earnings Per Share (TTM)?

The Omnicell EPS (TTM) is 0.43.

When Is the Next Omnicell Earnings Date?

Omnicell will release its next earnings report on Feb 05, 2026.

From a Technical Analysis Perspective, Is OMCL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Omnicell Stock Split?

Omnicell has split 0 times.

How Many Employees Does Omnicell Have?

Omnicell has 3600 employees.

What is the current trading status of Omnicell (OMCL)?

As of Jan 26, 2026, Omnicell (OMCL) is trading at a price of 50.38, with a previous close of 50.30. The stock has fluctuated within a day range of 50.07 to 51.00, while its 52-week range spans from 22.66 to 55.00.

What Is Omnicell (OMCL) Price Target According to Analysts?

The average 12-month price target for Omnicell is USD55.00, with a high estimate of USD63 and a low estimate of USD50. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +9.17% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.